363 related articles for article (PubMed ID: 33524794)
1. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract][Full Text] [Related]
2. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Myc transcriptional activity by a mini-protein based upon Mxd1.
Demma MJ; Hohn MJ; Sun A; Mapelli C; Hall B; Walji A; O'Neil J
FEBS Lett; 2020 May; 594(10):1467-1476. PubMed ID: 32053209
[TBL] [Abstract][Full Text] [Related]
4. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
5. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ; Mapelli C; Sun A; Bodea S; Ruprecht B; Javaid S; Wiswell D; Muise E; Chen S; Zelina J; Orvieto F; Santoprete A; Altezza S; Tucci F; Escandon E; Hall B; Ray K; Walji A; O'Neil J
Mol Cell Biol; 2019 Nov; 39(22):. PubMed ID: 31501275
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME; Jauset T; Massó-Vallés D; Martínez-Martín S; Rahl P; Maltais L; Zacarias-Fluck MF; Casacuberta-Serra S; Serrano Del Pozo E; Fiore C; Foradada L; Cano VC; Sánchez-Hervás M; Guenther M; Romero Sanz E; Oteo M; Tremblay C; Martín G; Letourneau D; Montagne M; Morcillo Alonso MÁ; Whitfield JR; Lavigne P; Soucek L
Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894502
[TBL] [Abstract][Full Text] [Related]
7. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
McAnulty J; DiFeo A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322239
[No Abstract] [Full Text] [Related]
8. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.
Madden SK; de Araujo AD; Gerhardt M; Fairlie DP; Mason JM
Mol Cancer; 2021 Jan; 20(1):3. PubMed ID: 33397405
[TBL] [Abstract][Full Text] [Related]
9. The long journey to bring a Myc inhibitor to the clinic.
Whitfield JR; Soucek L
J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34160558
[TBL] [Abstract][Full Text] [Related]
10. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.
Local A; Zhang H; Benbatoul KD; Folger P; Sheng X; Tsai CY; Howell SB; Rice WG
Mol Cancer Ther; 2018 Jun; 17(6):1177-1186. PubMed ID: 29626127
[TBL] [Abstract][Full Text] [Related]
11. A big step for MYC-targeted therapies.
Atibalentja DF; Deutzmann A; Felsher DW
Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
[TBL] [Abstract][Full Text] [Related]
12. Alternative approaches to target Myc for cancer treatment.
Wang C; Zhang J; Yin J; Gan Y; Xu S; Gu Y; Huang W
Signal Transduct Target Ther; 2021 Mar; 6(1):117. PubMed ID: 33692331
[TBL] [Abstract][Full Text] [Related]
13. Taking on challenging targets: making MYC druggable.
Horiuchi D; Anderton B; Goga A
Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
[TBL] [Abstract][Full Text] [Related]
14. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
15. MYC-mediated synthetic lethality for treating tumors.
Li X; Zhang XA; Li X; Xie W; Huang S
Curr Cancer Drug Targets; 2015; 15(2):99-115. PubMed ID: 25553514
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule modulators of c-Myc/Max and Max/Max interactions.
Berg T
Curr Top Microbiol Immunol; 2011; 348():139-49. PubMed ID: 20680803
[TBL] [Abstract][Full Text] [Related]
18. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
19. OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors.
Jung LA; Gebhardt A; Koelmel W; Ade CP; Walz S; Kuper J; von Eyss B; Letschert S; Redel C; d'Artista L; Biankin A; Zender L; Sauer M; Wolf E; Evan G; Kisker C; Eilers M
Oncogene; 2017 Apr; 36(14):1911-1924. PubMed ID: 27748763
[TBL] [Abstract][Full Text] [Related]
20. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
